Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 36 Neoplasm Metastasis 12 Neoplasms 10 Colorectal Neoplasms 5 Thyroid Neoplasms 4 Thyroid Cancer, Papillary 4 Multiple Myeloma 4 Leukemia, Hairy Cell 4 Hematologic Neoplasms 4 Skin Neoplasms 3 Pancreatic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Thyroid Carcinoma, Anaplastic 2 Recurrence 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Lymphoma, Non-Hodgkin 2 Brain Neoplasms 2 Thyroid cancer, follicular 1 Thrombocytosis 1 Sarcoma, Clear Cell 1 Sarcoma 1 Relapsed Pediatric Solid Tumor 1 Rare Tumour 1 Rare Tumor 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

atezolizumab 1 alectinib 1 Vemurafenib 1 Neoadjuvant Therapy 1 Fruit 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Genomic Instability × Vemurafenib × Clear all

NCT02314481 2026-05-04

DARWINII

University College, London

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Data powered by HemOnc (CC BY 4.0) Colophon ⚡